Center of Excellence for Modern Analytical Technologies (CEMAT), Zhejiang Huahai Pharmaceutical Co. Ltd., Xunqiao, Linhai, Zhejiang, 317204, PR China.
Quality Control Department of Chuannan Site, Zhejiang Huahai Pharmaceutical Co. Ltd., Duqiao, Linhai, Zhejiang, 317016, PR China.
J Pharm Biomed Anal. 2019 Oct 25;175:112788. doi: 10.1016/j.jpba.2019.112788. Epub 2019 Jul 24.
During the HPLC related substances testing of pregabalin API, an unknown peak was observed at a level exceeding the identification threshold. Preliminary investigation revealed that this impurity is not a process impurity but rather an artifactual solution degradant or "ghost peak" during the HPLC analysis. By using a strategy that combines LC-PDA/UV-MS with mechanism-based stress studies, the unknown peak was rapidly identified as a covalent adduct formed between pregabalin and acetonitrile (the latter is a component of the HPLC sample diluent), which is structurally an ethylamidine derivative of pregabalin. It appeared that the formation of this solution degradant was catalyzed by alkaline impurities during the sample preparation. This plausible mechanism was verified by a mechanism-based forced degradation study, in which a base was added into the sample diluent and consequently, the pregabalin-acetonitrile adduct was produced extremely efficiently at a level of ˜92%. Subsequently, the structure of the solution degradant was confirmed as an ethylamidine derivative of pregabalin through characterization by 1D and 2D NMR; the formation of the ethylamidine moiety is apparently via a nucleophilic attack on the cyano group of acetonitrile by the amino group of pregabalin. Due to the extensive presence of primary and secondary amine moieties in drug substances, this kind of artifactual solution degradation would likely occur during the sample preparations of these amine drugs in their HPLC analyses. In a GMP environment, such an event would trigger undesirable out-of-specification (OOS) investigations. The results of this study should help resolve such OOS investigations or prevent their happening from the very beginning. Furthermore, the somewhat surprising finding of the rather facile reaction that produces the ethylamidine moiety using simple alkylnitrile reagents, such as acetonitrile, may be of practical value in the synthesis of alkylamidines.
在培加滨原料药的 HPLC 相关物质检测中,观察到一个未知峰,其水平超过了鉴定阈值。初步调查显示,该杂质不是工艺杂质,而是在 HPLC 分析过程中产生的人为溶液降解物或“鬼峰”。通过采用结合 LC-PDA/UV-MS 与基于机制的应力研究的策略,迅速鉴定出未知峰为培加滨与乙腈(后者是 HPLC 样品稀释剂的组成部分)形成的共价加合物,其结构为培加滨的乙基脒衍生物。似乎是在样品制备过程中,碱性杂质催化了这种溶液降解物的形成。通过基于机制的强制降解研究验证了这一合理的机制,即在样品稀释剂中加入碱,随后在 ˜92%的水平下非常有效地产生了培加滨-乙腈加合物。随后,通过一维和二维 NMR 对该溶液降解物的结构进行了表征,确认其为培加滨的乙基脒衍生物;乙脒部分的形成显然是通过培加滨的氨基对乙腈的氰基进行亲核攻击。由于药物物质中广泛存在伯胺和仲胺部分,因此在这些胺类药物的 HPLC 分析中进行样品制备时,可能会发生这种人为的溶液降解。在 GMP 环境中,此类事件将引发不合规(OOS)调查。该研究的结果应有助于解决此类 OOS 调查或从一开始就防止其发生。此外,使用简单的烷基腈试剂(如乙腈)生成乙脒部分的相当容易的反应的发现有些令人惊讶,这在烷基脒的合成中可能具有实际价值。